Early-stage Opportunity Target a biotech partner or contract development organization to advance the PPDS platform, leveraging Mati Therapeutics' ongoing glaucoma and ocular hypertension focus to co-develop or license the technology for late-stage trials and commercialization.

Strategic Collaboration Position the company for collaboration with ophthalmology device manufacturers and eye-care chronic disease players to integrate PPDS into existing punctal plug ecosystems, offering a minimally invasive, sustained-release solution for glaucoma therapies.

Clinical Pipeline Fit Market opportunities around delivering anti-inflammatories and potential dry eye or ocular allergy therapies through PPDS, aligning with ophthalmology clinics seeking innovative, office-based delivery methods.

Funding & Growth With current funding and a small team, identify grant opportunities, early-stage partnering programs, or milestone-driven deals to de-risk development while preserving Mati’s ownership as they advance toward pivotal trials.

Key Contacts Coordinating with Mati’s leadership, particularly the COO appointed in 2023, to establish strategic outreach targets at ophthalmology groups, device manufacturers, and specialty pharma players active in glaucoma and ocular surface diseases.